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The prevalence of invasive aspergillosis (IA) at the 
intensive care unit (ICU) is unknown and difficult to 
assess since IA also develops in patients lacking 
specific host factors. In the Netherlands, increasing 
azole-resistance in Aspergillus fumigatus complicates 
treatment of patients with IA. The aim of this study 
was to determine the prevalence of IA by azole-resist-
ant A. fumigatus at the ICU among patients receiving 
antifungal treatment and to follow their clinical out-
come and prognosis. A retrospective cohort study was 
conducted in a university hospital ICU from January 
2010 to December 2013. From all patients who received 
antifungal treatment for suspected IA, relevant clinical 
and microbiological data were collected using a stand-
ardised questionnaire. Of 9,121 admitted ICU-patients, 
136 had received antifungal treatment for suspected 
IA, of which 38 had a positive A. fumigatus culture. 
Ten of the 38 patients harboured at least one azole-
resistant isolate. Resistance mechanisms consisted 
of alterations in the cyp51A gene, more specific TR34/
L98H and TR46/T289A/Y121F. Microsatellite typing did 
not show clonal relatedness, though isolates from two 
patients were genetically related. The overall 90-day 
mortality of patients with IA by azole-resistant A. 
fumigatus and patients with suspicion of IA by azole-
susceptible isolates in the ICU was 100% (10/10) vs 
82% (23/28) respectively. We conclude that the chang-
ing pattern of IA in ICU patients requires appropriate 
criteria for recognition, diagnosis and rapid resist-
ance tests. The increase in azole resistance rates also 
challenges a reconsideration of empirical antifungal 
therapy.
Introduction
Azole resistance is an emerging problem in Aspergillus 
infections caused by Aspergillus fumigatus, with 
increasing reports of azole treatment failure [1-6]. 
Although azole resistance can develop during azole 
therapy, exposure to azole compounds used in the 
environment appears to contribute to a greater extent 
[1,2,7]. Surveillance studies increasingly report geo-
graphical spread of azole resistance in environmental 
and clinical A. fumigatus isolates, including in Europe, 
Asia, the Middle East, Africa and most recently North 
and South America [4,8-10]. In contrast, surveillance 
studies from the Netherlands revealed azole resistance 
to be endemic, with dominance of the TR34/L98H and 
TR46/Y121F/T289A cyp51A-gene mediated resistance 
mechanisms [3]. These studies were based on routinely 
screening for the presence of azole resistance in all 
Aspergillus spp. isolates cultured from clinical samples 
in five university hospitals, irrespective of the clini-
cal relevance of the culture result [3]. Although these 
surveys provide insight in the overall prevalence of 
azole resistance in culture-positive patients, the impli-
cations of azole resistance for specific patient groups 
remain unknown. In recent years, new categories of 
patients, lacking specific host factors as defined by 
the European Organization for Research and Treatment 
of Cancer/Mycoses Study Group (EORTC/MSG), such 
as intensive care unit (ICU) patients, are increasingly 
recognised for their susceptibility to develop IA. Thus 
the reported prevalence of invasive aspergillosis (IA) 
has increased at the ICU [11-13]. As information on IA 
by azole-resistant A. fumigatus in the ICU is scarce, 
we performed a retrospective cohort study in order to 
investigate the prevalence of azole resistance and its 
implications for patient treatment.
Methods
Study population
A retrospective cohort study was conducted in a 33-bed 
tertiary university hospital ICU in the Netherlands. 
Patients were identified by running a query for the 
period from January 2010 to December 2013 as those 
prescribed with voriconazole, conventional ampho-
tericin B (c-AmB) or liposomal amphotericin B (L-AmB). 
Patients receiving mold-active drugs as prophylaxis 
only or antifungal therapy for non-Aspergillus fungal 
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infections were excluded. Furthermore, patients sus-
pected for IA, but where A. fumigatus could not be 
grown, were excluded as well. Thus, the study popu-
lation consisted of ICU patients who were treated for 
suspected IA and in whom A. fumigatus was cultured, 
since resistance testing can only be done on cultured 
isolates.
Ethical consideration
Due to the retrospective design and report on anony-
mous patient data, ethical approval was not required.
Diagnosis of invasive aspergillosis
All patients with a clinical syndrome suspected for IA 
underwent computed tomography (CT)-scanning and 
bronchoscopy for histological and microbiological 
examinations, unless clinical respiratory condition did 
not allow interventions or transportation. In addition to 
the bronchoalveolar lavage (BAL) or lung biopsy, sup-
plementary samples were occasionally available for 
galactomannan test or culture, such as serum, tracheal 
aspirate or sputum. Antifungal treatment was admin-
istered to all patients with specific CT lesions (among 
others halo sign) and a positive culture or Aspergillus 
biomarker in serum or BAL. Since CT lesions are 
only present in a minority of the ICU population [14], 
patients with a high clinical suspicion of IA (based on 
host characteristics and exclusion of an alternative 
diagnosis) and a positive respiratory or serum sam-
ple were treated as well. Following local and national 
guidelines, first choice treatment was voriconazole. 
When azole resistance was suspected or severe abnor-
mal liver function tests were present, L-AmB or c-AmB 
were prescribed.
Data collection
Electronic patient records (EZIS-Chipsoft, iMDsoft, 
GLIMS) were searched by the investigators (AitV, AR, 
JvP). Data regarding host factors, CT reports, micro-
biology results, mortality and use of prior antifungal 
therapy in the past 6 months were extracted from the 
hospital information system using a pre-assessed 
questionnaire. The EORTC/MSG criteria were applied to 
categorise patients as proven IA, probable IA or unclas-
sified [15]. Since these criteria have been reported as 
less suitable for ICU patients, the ICU-criteria of Blot et 
al. were also used to classify patients with proven IA, 
putative IA or colonisation [16].
Microbiology
BAL fluids were tested for galactomannan (Platelia 
Aspergillus EIA, Bio-Rad, the Netherlands) using the 
recommended cut-off index of 0.5 for positivity. Direct 
microscopy was performed using the optical bright-
ener calcofluor white on the sediment of the BAL fluid. 
Cultures for yeast and fungi were performed using 
standard techniques [17], including use of a selective 
Sabouraud dextrose agar incubated for 1 week at 35°C. 
If the culture was positive, Aspergillus species were 
identified to the species complex level using macro-
scopic and microscopic morphology. In addition, the 
ability of the fungus to grow at 48 °C was used to iden-
tify A. fumigatus species complex. 
From cultures yielding A. fumigatus, up to four colonies 
were subcultured on a four-well agar plate to screen 
for azole resistance. In three wells the agar was sup-
plemented with itraconazole (4 mg/L), voriconazole 
(1 mg/L), or posaconazole (0.5 mg/L). The fourth well 
served as growth control. Growth was assessed after 
24 and 48 hours of incubation and any growth on the 
agars supplemented with azoles was indicative of pos-
sible azole resistance. These isolates were further ana-
lysed at the Mycology Reference Laboratory (Radboud 
Figure 1
Flow-chart of patient selection to investigate the 
prevalence of invasive aspergillosis by azole-resistant 
Aspergillus fumigatus in the intensive care unit of a 
university hospital, Netherlands, 2010–2013 (n=38 selected 
patients)
197 patients
on antifungal therapy
33 double therapy
21 prophylaxis only
7 other molds than A. fumigatus
136 patients treated
(suspected of IA)
38 patients
positive culture for IA
10 patients with
resistant IA
28 patients with
susceptible IA
IA: invasive aspergillosis.
Figure 2
Distribution of patients treated for suspected invasive 
aspergillosis in the intensive care unit of a university 
hospital, Netherlands, 2010–2013 (n=136 patients)
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University Medical Centre, Nijmegen), including molec-
ular identification, azole resistance phenotype and 
resistance genotype [3]. The mimimum inhibition con-
centration (MIC) was determined using the European 
Committee on Antimicrocial Susceptibility Testing 
(EUCAST) broth microdilution reference method [18]. 
Azole resistance was defined as a MIC-value > 2 mg/L 
for itraconazole and/or voriconazole and/or a MIC-
value > 0.25 mg/L for posaconazole [18].
Microsatellite typing was retrospectively performed 
on available isolates by the Mycology Reference 
Laboratory (Nijmegen), as described previously [19]. In 
summary, six short tandem repeats (STR) were selected 
and amplified in two multiplex polymerase chain reac-
tions (PCR)s. The repeat numbers of the six markers 
were analysed by Bionumerics version 4.6, software 
(Applied Maths, Kortrijk, Belgium). The summed abso-
lute distance between two multilocus variable-number 
tandem repeat analysis (MLVA)-typed isolates is the 
summed tandem-repeat differences (STRD) at six mark-
ers. Isolates with an STRD ≤ 10 were defined as geneti-
cally related, irrespective of the number of differing 
loci. Clonal complexes were defined as by an STRD ≤ 2 
provided that isolates were single-locus variants or 
double-locus variants of one another.
Endpoints
The primary endpoint was the prevalence of IA by 
azole-resistant A. fumigatus at the ICU. Secondly, we 
investigated patient characteristics coinciding with 
resistant IA, such as pre-treatment with azoles, under-
lying illness, and IA probability according to EORTC/
MSG criteria [15]. Moreover, 90-day mortality and 
cause of death were assessed. Furthermore, we com-
pared ICU prevalence of IA by azole-resistant A. fumig-
atus with the prevalence in the same period in the rest 
of the hospital.
Data analyses
Descriptive statistics were used for primary analysis 
and assessment of clinical relevance. A formal risk 
assessment with multivariate analyses could only be 
performed in the presence of enough events, in order 
to prevent false positive results.
Results
During the study period, 197 prescriptions of voricona-
zole, c-AmB or L-AmB were identified in the ICU. Thirty-
three patients received both voriconazole and c-AmB or 
L-AmB and appeared twice in the search. Twenty-eight 
patients were excluded; 21 patients received antifun-
gal prophylaxis, and seven patients were treated for 
proven fungal infection due to yeast or fungi other than 
A. fumigatus. Consequently, a total of 136 patients were 
treated for suspected IA, representing 15 patients per 
1,000 admissions at the ICU. A culture for A. fumigatus 
had been attempted for all 136 patients. Of these, 38 
(28%) had a positive culture for A. fumigatus and were 
analysed further (Figure 1).
Azole resistance prevalence
Azole-resistant isolates were not recovered in 2010, 
but in the two following years a total of 10 culture-
positive patients with resistant isolates were identified 
(Figure 2). Azole resistance was present in 10 of the 38 
culture-positive patients (26%), which corresponds to 
7% (10/136) of all patients receiving antifungal treat-
ment in the ICU from January 2010 to December 2013, 
including culture-negative patients. In all other depart-
ments in the hospital, of all patients treated for sus-
pected IA, A. fumigatus was cultured in 25 patients. Six 
of these patients had an azole resistant strain, yield-
ing an azole resistance prevalence of 24% (6/25) (95 % 
confidence interval (CI): 7–41%), which was seemingly 
comparable to that in the ICU.
Clinical characteristics of Aspergillus fumigatus 
culture positive patients in the intensive care 
unit
No differences were found in patient characteristics 
between the 10 patients with IA by azole-resistant A. 
fumigatus when compared with 28 patients with sus-
ceptible isolates (Table 1). Our low number of events 
(n=10) unfortunately prevented us from doing multi-
variable analysis.
Underlying disease
In the entire study group encompassing 38 patients 
with suspected IA in the ICU, 16 underwent a hae-
matopoietic stem cell transplantation and four suf-
fered from haematological malignancy, but were not 
yet transplanted (Table 1). Three patients had chronic 
immunosuppressive therapy for solid organ trans-
plants. Other host factors included autoimmune dis-
ease (n = 6), history of pulmonary disease (n=6: cancer, 
chronic obstructive pulmonary disease (COPD), irradia-
tion) and the admission diagnoses of the remaining 
three patients were heart failure, acute liver failure, 
and severe disseminated infection with Strongyloides 
stercoralis.
Diagnosing invasive aspergillosis using international 
criteria
Of 28 patients with an azole-susceptible A. fumiga-
tus infection, 15 were classified as probable IA, while 
proven IA was only established in two. Eleven of 28 
patients with an azole-susceptible strain did not fulfil 
EORTC/MSG criteria of proven, probable or possible IA, 
most often due to lack of host factor, inconclusive CT 
scan or inability to perform a CT scan. Of 10 patients 
with an azole-resistant A. Fumigatus, five patients 
remained unclassified according to the EORTC/MSG 
criteria; in three cases, CT scans showed unspecific 
changes and two patients were not stable enough to 
be transported to the CT scan, but did show bilateral 
pulmonary infiltrates on the chest X-ray. The other 
five qualified as probable IA. Overall 22 of 38 patients 
could be classified according to EORTC/MSG. 
Except for one patient, who was on ‘Extra Corporeal 
Membrane Oxygenator’ (ECMO) therapy for heart 
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failure, applying the recently published ICU criteria of 
Blot et al. [16], allowed classification of all patients 
with an A. fumigatus positive culture. ECMO therapy 
hampers the assessment of A. fumigatus-related clini-
cal signs and symptoms (fever, dyspnoea, worsening 
of respiratory insufficiency), since they are regulated 
by the device itself. According to this system, a total of 
two patients, both infected with an azole-susceptible 
strain, had proven IA. A further twenty-one patients 
with an azole-susceptible strain qualified as having 
putative IA as well as all 10 patients with azole-resist-
ant A. fumigatus. Only four patients, all with an azole-
susceptible A. fumigatus isolate, were classified as 
colonised with Aspergillus according to Blot’s criteria. 
For one of these (with a BAL), post-mortem results indi-
cated angio-invasive aspergillosis. For the other three 
patients, difficult mechanical ventilation prohibited the 
performance of BAL. After intubation, a tracheal aspi-
rate with a positive A. fumigatus culture was however 
available for these three patients. EORTC criteria would 
classify one of them as probable invasive pulmonary 
aspergillosis, while post-mortem findings in another 
were consistent with angio-invasive aspergillosis. In 
the fourth patient the diagnosis allergic broncho-pul-
monary aspergillosis (ABPA) was made.
Azole prophylaxis
The relative amount of patients receiving prior treat-
ment with azoles appeared higher in the group devel-
oping IA due to resistant A. fumigatus. The low number 
of events however prohibited a formal statistical risk 
assessment (Table 1).
Microbiological characteristics of Aspergillus 
fumigatus culture-positive patients at the 
intensive care unit
Galactomannan in bronchoalveolar lavage fluids
Overall of the 136 patients treated in the ICU on suspi-
cion of IA, galactomannan testing was performed for 
124, mostly on BAL fluids. In 82 of these 124 patients 
antigen testing was positive. 
Figure 3
Microsatellite typing of azole-resistant Aspergillus fumigatus isolates, in a university hospital, Netherlands, 2013 (n=7 
patients)
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In 38 of the 136 patients A. fumigatus could be cultured. 
A BAL was not performed in five of the 38 culture-posi-
tive patients, since a lung biopsy was available for one 
patient, serum galactomannan was positive in another 
neutropenic patient and clinical condition did not allow 
interventions in three patients. In 33 patients who 
underwent BAL, 29 had samples positive by galacto-
mannan testing.
Time to detection of resistant strain
In most of the 10 ICU patients found with a resistant 
strain, the resistant strain was cultured before admis-
sion, or shortly after admission at the ICU, whereby the 
time after ICU admission that it took to be aware of the 
resistance had a median 1 day and a range of 0 to 20 
days. In the six patients with azole-resistant strains at 
the non-ICU departments, resistant strains could also 
be cultured shortly after hospital admission (median 4 
days; range: 1–71 days) (Table 2).
Resistance mechanisms and microsatellite typing
A cyp51A-mediated azole resistance mechanism was 
found in all ICU patients (Table 2). Microsatellite typing 
was available for resistant isolates of seven patients (4 
from ICU population, 3 from non-ICU departments), all 
cultured in 2013 (Figure 3). Isolates of unique patients 
belonged to identical clonal complexes, although for 
one patient the presence of two genetically unrelated 
strains was revealed. These strains differed also phe-
notypically, with isolates either susceptible or with 
varying degrees of resistance. Only two patients, one 
hospitalised in the ICU the other elsewhere, shared 
a genetically related isolate (Figure 3; STDR < 10), but 
we did not find an epidemiological link between these 
patients.
Outcome
The 90-day mortality in 10 patients with an IA by azole-
resistant A. fumigatus was 100% (with 90% within 30 
days after ICU admission), compared with 82% (n=23) 
Table 1
Characteristics of patients with isolates of Aspergillus fumigatus susceptible or resistant to azoles, in the intensive care unit 
of a university hospital, the Netherlands, 2010–2013 (n=38 patients)
Characteristics
Azole-resistant 
N = 10 
n
Azole-susceptible 
N = 28 
n
Mean age in years (range) 52 (24–69) 58 (1–85) 
Underlying disease 
Haematological malignancy/stem cell transplant 6 14 
Solid organ transplant 1 2 
Othera 3 12 
Prophylaxis in prior 6 months 
None 3 14
Azoles 6 11 
Treatment for IA 
Voriconazole 6 17
Amphotericin 4 4
Switch from azole to amphotericin 0 7 
BAL results 
BAL available 10 23b
Galactomannan positive 9 20 
EORTC/MSG diagnosis 
Proven 0 2 
Probable 5 15 
Unclassified 5 11 
Diagnosis according to Blotc 
Proven 0 2 
Putative 10 21
Colonisation 0 4 
BAL: bronchoalveolar lavage; EORTC/MSG: European Organization for Research and Treatment of Cancer/Mycoses Study Group; IA: invasive 
aspergillosis.
a This group comprised patients with auto-immune disease (n=6), pulmonary disease (n=6), heart failure (n=1), acute liver failure (n=1), and 
severe disseminated infection with Strongyloides stercoralis (n=1).
b BAL was not performed in six patients: two of these patients underwent biopsy, one patient had a positive serum galactomannan and the 
clinical condition of the three remaining patients did not allow BAL.
c One patient on the Extra Corporeal Membrane Oxygenator (ECMO) - device could not be classified.
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in the 28 patients with a suspected azole-susceptible 
IA. Given that among the latter, one patient on ECMO 
was neither classifiable by Blot nor EORTC/MSG meth-
ods, and one patient, who was classified as colonised 
according to Blot might have actually been colonised 
(since he was diagnosed with BCPA), the 90-day mor-
tality in azole-suceptible IA-group would be 88 % 
(23/26). 
In the group of patients infected with azole-resistant 
strains, cause of death was IA in all patients, except 
one. This patient’s clinical course was most likely unfa-
vourable due to acute liver failure after a very recent 
liver transplantation. Of 28 patients infected with 
azole-susceptible A. fumigatus, the cause of death 
was attributable to IA in seven patients, whereas five 
patients died of respiratory failure caused by multiple 
pathogens and 11 patients died of other causes than IA 
(heart failure, sepsis, liver failure). 
In four of 10 patients infected with azole-resistant A. 
fumigatus, azole resistance was detected after the 
patient had deceased. Hence, only six of 10 patients 
with a resistant isolate were treated with L-AmB, of 
which four received treatment for over 2 weeks (Table 
1).
Discussion
Our study shows a very high prevalence (10/38) of 
azole-resistant A. fumigatus in patients suspected of 
IA in the ICU of a university hospital in the Netherlands. 
This prevalence is even higher (10/33) among patients 
with putative or proven IA according to the Blot crite-
ria, whereby patients classified as ‘colonised’ with A. 
fumigatus are excluded. Both prevalence estimates 
nevertheless appear much higher than those reported 
in two previously published large Dutch surveillance 
studies [1-3], where, irrespective of the clinical rel-
evance of the culture result, all Aspergillus spp. iso-
lates cultured from clinical samples in five university 
hospitals were routinely screened for the presence of 
azole resistance. In the first study covering the 2007 
to 2009 period, azole resistance was found in 4.6% 
(82/1,782) of A. fumigatus isolates [3], while in the sec-
ond study, between 2009 and 2011, this increased to 
6.8% (63/921) of such isolates [2]. 
Prevalence of azole resistance in specific patient groups 
has only been recently investigated. A published report 
from another academic centre in the Netherlands, 
revealed a high incidence of azole resistance (16.2%) 
in 105 high-risk patients with IA, with an even higher 
value in the haematology population (25%) and 10% 
in ICU patients [20]. Similarly, a high azole-resistance 
rate of 29.6% was demonstrated in A. fumigatus iso-
lates from haematological stem cell transplant patients 
in Germany [6]. Our study also shows high prevalence 
of resistance in other departments of our hospital. 
Although no known risk factors for developing IA by 
azole-resistant A. fumigatus were apparent, one could 
speculate that patients with IA who are transferred to 
the ICU are those whose condition deteriorates despite 
voriconazole treatment in the hospital wards, and thus 
are more likely to carry a resistant strain. Resistance 
rates could be overestimated due to the use of anti-
fungal therapy at the time BAL is performed, because 
azole-susceptible strains are less likely to grow under 
mold-active therapy. Furthermore, as tertiary stem cell 
and solid organ transplant centre, our patient popu-
lation is probably not representative for most ICUs in 
other hospitals. The conclusions from this study, which 
are also based on small numbers of patients, therefore 
cannot be applied to other ICUs with a higher number 
of immunocompetent patients.
Recognition of IA and start of empirical treatment 
remains difficult at the ICU. First of all, diagnostic cri-
teria for patients with suspected IA are suboptimal. As 
demonstrated in this study, EORTC/MSG consensus 
definitions for IA are not generally applicable for ICU-
patients: only 22 of 38 culture-positive patients could 
be classified. Second, new categories of ICU patients 
susceptible to invasive pulmonary aspergillosis, are 
increasingly reported [11,12,21]. Since these new cat-
egories of ICU patients lack the host-factors defined 
by EORTC/MSG consensus definition, new criteria 
have been proposed for ICU-patients [11,16,21]. Blot 
et al. suggested a different algorithm that appears to 
be more suitable, although some patient categories at 
risk, for instance liver failure, COPD, and solid organ 
cancer, are not included in these diagnostic criteria 
[11,16]. When applying the criteria of Blot to our group 
of 38 ICU patients, 37 of the patients could be cat-
egorised, though in two patients, classified as ‘colo-
nisation’, post-mortem findings were congruent with 
angio-invasive aspergillosis, and one would be diag-
nosed probable IA, if one would use EORTC/MSG cri-
teria, illustrating the restraints of this scoring system. 
Hence, development of better clinical criteria for diag-
nosing IA, especially in ICU patients, is warranted [16].
Multiple mechanisms can be considered with regard to 
the development of azole resistance in A. fumigatus. In 
our study we found a short interval from admission to 
detection of a resistant strain (median 3 days, mean 8 
days; range: 0–71days). Moreover, molecular typing, 
did not reveal genetically-related strains, suggesting 
different sources of infection, instead of an outbreak 
of azole-resistant A. fumigatus or patient-to-patient 
transmission. This could imply that acquirement of 
resistant strains could have occurred before hospital 
admission. Some reports suggests an increase of prev-
alence of resistant A. fumigatus strains in the environ-
ment [2,22]. The use of fungicides in the agricultural 
sector might contribute to this phenomenon [1]. Other 
reports suggest development of azole resistance dur-
ing therapy. A review regarding this subject reports a 
median time for development of resistance under ther-
apy of 4 months, with a range of 3 weeks to 23 month 
[23]. In our study the number of events was too small 
to rule out prior treatment or prophylaxis with azoles 
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as a risk factor. Finally, other studies suggest the con-
comitant presence of both susceptible and resistant 
strains in patient samples [24], resulting in a selection 
of resistant strains during therapy. It is not unlikely 
that all of the mechanisms mentioned above contribute 
to an observed increase of resistance in patients with 
A. fumigatus infections, making it difficult to predict 
which patients are carriers of a resistant strain.
Additionally, identifying IA with azole-resistant A. 
fumigatus is still dependent on culture-positivity and 
technical facilities. From the 136 patients initially sus-
pected of IA in the ICU, 124 underwent the galactoman-
nan test, which was positive for 82 (66%). In contrast 
A. fumigatus could only be successfully cultured in 
28% (38/136) of patients suspected of IA in the ICU. 
In this culture positive group BAL galactomannan was 
more frequently positive (29/33). Hence a negative cul-
ture may not necessarily mean the absence of IA.
Currently, the presence of resistance can be established 
only in culture-positive patients. In culture-positive 
patients, detection of azole resistance is often delayed, 
since MIC-testing of A. fumigatus is not routinely per-
formed in clinical microbiology laboratories. Reference 
methods such as the EUCAST method require a mature 
culture and testing results are available 5 to 7 days 
after the culture has become positive. Screening of 
isolates with four-well plates has been shown to be 
useful and gives results within 24 to 48 hours, but this 
method is not commercially available [1,3].
Direct molecular testing for azole resistance in patients 
with high clinical suspicion and a positive antigen 
testing of BAL fluid appears to be the most promising 
method for early detection of azole-resistant A. fumiga-
tus [25-27]. However, there are several technical issues 
to be resolved, such as the presence of single copy 
gene mutations of the cyp51A gene limiting the sensi-
tivity of PCR detection. The most frequent found azole 
resistance mechanism in A. fumigatus is a mutation 
in the target protein [2,5]. The cyp51A gene encodes 
lanosterol 14α-demethylase that catalyses a step in 
the biosynthetic pathway of ergosterol (an essential 
Table 2
Characteristics of patients infected with azole-resistant Aspergillus fumigatus in a university hospital, Netherlands, 2010–
2013 (n=16)
Patient 
numbera Predisposing condition
EORTC 
classification
Time in days from 
admission to 
finding a culture 
of resistant A. 
fumigatus
Underlying lung 
disease
Neutropenia 
at admission
Azole pre- 
treatment
MICb 
(mg/L) Resistance 
mechanism
Itra.b Vori. b Posa.b
ICU population 
1 Liver transplant Unclassified 4 No No No 16 16 1 TR34/L98H
2 Autoimmune hepatitis (prednisone) Unclassified 0 No No No > 16 > 16 1
TR46/T289A/
Y121F
3 Allogeneic SCT Unclassified 1 No No NA > 16 > 16 1 TR46/T289A/Y121F
4 Allogeneic SCT Probable 20 No No No 16 16 1 TR34/L98H
5 Haematological malignancy Probable 1 No No No 16 16 1
TR46/T289A/
Y121F
6 Allogeneic SCT Probable 0 No No > 6 months > 16 8 1 TR34/L98H
7 NSCLC (prednisone) Probable 0 NSCLC No No 16 4 0.5 TR34/L98H
8 COPD (prednisone) Unclassified 6 COPD No No > 16 > 16 1 TR34/L98H
9 Allogeneic SCT Probable 0 No Yes > 3 months 16 8 1 TR34/L98H
10 Allogeneic SCT Unclassified 5 No No 11 days 16 8 2 TR34/L98H
Non-ICU population 
1 Allogeneic SCT Probable 71 Bronchiectasis No No 16 0.5 8 NA
2 Waldenström’s macroglobulinaemia Unclassified 8 No No No > 16 0.5 4 NA
3 COPD (prednisone) Unclassified 3 COPD GOLD stage IV No No > 16 4 > 16 NA
4 Allogeneic SCT Probable 1 No No > 4 weeks 16 1 16 NA
5 Autoimmune hepatitis (prednisone) Probable 3 Influenza No No 2 1 > 16
TR46/T289A/
Y121F
6 Autoimmune vasculitis (prednisone) Probable 4
ANCA positive 
vasculitis Yes No > 16 0.5 > 16 Not detected
ANCA: antineutrophil cytoplasm antibodies; COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; 
ICU: intensive care unit; EORTC: European Organization for Research and Treatment of Cancer; MIC: minimum inhibitory concentration; NA: not available; 
NSCLC: non-small cell lung carcinoma; SCT: stem cell transplant.
a The patient number is assigned consecutively within each patient population (i.e. ICU or non-ICU) so patients belonging to separate population groups but with 
the same number are different patients.
b MICs were evaluated for itraconazole (itra.), voriconazole (vori.), or posaconazole (posa.).
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cell membrane component of filamentous fungi). Both 
TR34/L98H, conferring cross-resistance to voricona-
zole and posaconazole and TR46/T289A/Y121F, confer-
ring high level voriconazole resistance, were present 
in our patients’ isolates. These findings in the ICU are 
in line with surveillance studies in the Netherlands, 
indicating that environmental azole resistance mecha-
nisms (i.e. TR34/L98H and TR46/Y121F/T289A) are the 
most common cause of azole resistance, accounting for 
80 to 90% of resistance mechanisms [2].
High resistance rates urge us to explore alternative 
(empirical) treatment strategies for IA [28]. These 
include first-line treatment with a polyene or with com-
bination therapy. The clinical experience with these 
alternative treatment options is very limited, but ani-
mal models showed similar efficacy of L-AmB in IA by 
azole-susceptible and azole-resistant isolates, inde-
pendent of the underlying resistance mechanism [29]. 
The combination of voriconazole and anidulafungin 
has also been shown to be effective [30]. MIC-guided 
high dosing of azoles is still under investigation, but is 
probably of limited use due to adverse events [31,32].
In conclusion, we observed very high rates of azole 
resistance A. fumigatus in culture-positive ICU patients 
with IA and very high mortality rates among such 
patients. Generalising our results requires caution, 
though recent reports suggest that similar trends are 
observed among other patient groups [20,25]. There 
is an urgent need to identify molecular markers for 
resistance in A. fumigatus other than the cyp51A-gene 
in order to enable the development of rapid molecular 
tools. Development of adequate diagnostic criteria for 
early diagnosis and reliable classification remains a 
challenge in IA, especially in the ICU setting.
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